San Diego, CA (PRWEB) April 30, 2013
Stemedica Cell Technologies, Inc., a leading manufacturer of adult allogeneic stem cells and stem cell factors announced that the Company has been issued “keystone” Patent No. 8,420,394 titled “Culturing Ectodermal Cells Under Reduced Oxygen Tension” by the United States Patent and Trademark Office (USPTO). This patent broadly covers Stemedica’s proprietary manufacturing process for enhancing the proliferation and differentiation potential of ectodermal cells of any origin. The ectodermal layer gives rise to the cells of the skin and nervous system. The patented process provides Stemedica exclusivity for expanding and manufacturing ischemia tolerant ectodermal cells under reduced oxygen tension.
Nikolai Tankovich, MD, PhD, FASLMS, President and Chief Medical Officer of Stemedica noted, “We are pleased that the USPTO recognizes the uniqueness of the technology and processes to manufacture ectodermal cell of any origin. This includes, but is not limited to: allogeneic and autologous adult, embryonic, parthenogenic and iPS sources of stem cells. When compared to stem cells expanded in normal oxygen, Stemedica cells exhibit superior migratory and engraftment properties, enhanced gap junction formation and a unique gene profile. These critical cell characteristics are the direct result of Stemedica’s proprietary technology and expansion methodology.”
Alex Kharazi, MD, PhD, Chief Technology Officer at Stemedica noted that, “We recently published data from the spinal cord injury study in rats done by Ivan Cheng, MD, at Stanford University showing significant efficacy of Stemedica’s neural stem cells injected intrathecally both distally and at the site of injury. We also anticipate publishing extremely promising data in t
Copyright©2012 Vocus, Inc.
All rights reserved